计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
A414203-5mg |
5mg |
期货 ![]() |
| |
A414203-25mg |
25mg |
现货 ![]() |
| |
A414203-50mg |
50mg |
现货 ![]() |
| |
A414203-100mg |
100mg |
现货 ![]() |
|
英文别名 | 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate | BS-15747 | BDBM180052 | 1-Piperazinecarboxylic acid, 4-((2-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl)methyl)-2,2,2-trifluoro-1-(trifluoromethyl) |
---|---|
规格或纯度 | Moligand™, ≥98% |
英文名称 | ABX-1431 |
生化机理 | ABX-1431 是一种强效、选择性和中枢神经系统穿透性的单乙酰甘油脂肪酶(MGLL)抑制剂,对 hMGLL 和 mMGLL 的 IC50 值分别为 14 nM 和 27 nM。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | αβ-水解酶 6 抑制剂;单酰甘油脂肪酶抑制剂;聚乳酸 2-G7 抑制剂 |
产品介绍 |
Information ABX-1431 ABX-1431 is a highly potent, selective, and CNS-penetrant Monoacylglycerol lipase (MGLL) inhibitor with IC50 values of 14 nM and 27 nM for hMGLL and mMGLL respectively. Targets hMGLL ; mMGLL 14 nM; 27 nM In vitro ABX-1431 is a potent human MGLL inhibitor (average IC50 = 0.014 μM) with >100-fold selectivity against ABHD6 and >200-fold selectivity against PLA2G7. Treatment of intact human PC3 cells with ABX-1431 following a 30 min inhibitor incubation time causes concentration dependent inhibition of MGLL activity with an IC50 value of 0.0022 μM, which is ∼6-fold more potent than that observed in vitro. ABX-1431 inhibits MGLL via carbamoylation of the catalytic nucleophile Ser122. In vivo Pharmacokinetic analysis in rats and dogs of ABX-1431 indicate low to moderate systemic clearance, moderate volume of distribution, and high oral bioavailability (64% in rat, 57% in dog). While ABX-1431 is stable in human and dog plasma, it is not stable in rat plasma. ABX-1431 is a potent and selective inhibitor of MGLL in mouse and rat brain in vivo. ABX-1431 inhibits MGLL activity with an ED50 of 0.5-1.4 mg/kg (po) and dose-dependently increases brain 2-AG levels in mouse brain. A rat inflammatory pain model is used to assess the pharmacodynamics effect. ABX-1431 demonstrates potent antinociceptive effects in a formalin paw test at a dose that produced near complete MGLL inhibition and maximal elevation of 2-AG. Cell Research(from reference) Cell lines:PC3 cells Concentrations:0.1-10 μM Incubation Time:30 min |
ALogP | 5.372 |
---|---|
Rotatable Bond | 8 |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504772190 |
---|---|
EC号 | 870-188-4 |
分子类型 | 小分子 |
IUPAC Name | 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate |
INCHI | InChI=1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2 |
InChi Key | SQZJGTOZFRNWCX-UHFFFAOYSA-N |
Canonical SMILES | C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CN3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F |
Isomeric SMILES | C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CN3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F |
关联CAS | 1446817-84-0 |
PubChem CID | 71657619 |
MeSH Entry Terms | 1,1,1,3,3,3-Hexafluoro-2-propanyl 4-(2-(1-pyrrolidinyl)-4-(trifluoromethyl)benzyl)-1-piperazinecarboxylate;1-Piperazinecarboxylic acid, 4-((2-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl)methyl)-, 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester;ABX-1431 |
分子量 | 507.39 |
溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (197.08 mM); Ethanol: 100 mg/mL (197.08 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 100 |
DMSO(mM) Max Solubility | 197.087053351465 |
Water(mg / mL) Max Solubility | <1 |
分子量 | 507.400 g/mol |
XLogP3 | 5.200 |
氢键供体数Hydrogen Bond Donor Count | 0 |
氢键受体数Hydrogen Bond Acceptor Count | 13 |
可旋转键计数Rotatable Bond Count | 5 |
精确质量Exact Mass | 507.157 Da |
单同位素质量Monoisotopic Mass | 507.157 Da |
拓扑极表面积Topological Polar Surface Area | 36.000 Ų |
重原子数Heavy Atom Count | 34 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 670.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Purity(HPLC) | 98-100(%) |
---|---|
Proton NMR spectrum | Conforms to structure |
1. Cisar JS, Weber OD, Clapper JR, Blankman JL, Henry CL, Simon GM, Alexander JP, Jones TK, Ezekowitz RAB, O'Neill GP et al.. (2018) Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.. J Med Chem, 61 (20): (9062-9084). [PMID:30067909] [10.1021/op500134e] |